Skip to content
Medical Health Aged Care

RACGP urges RSV immunisation rollout to keep vulnerable Victorian infants safe

Royal Australian College of GPs 2 mins read

The Royal Australian College of GPs (RACGP) has called on the Victorian Government to follow other states’ lead and commit to rolling out an RSV immunisation program that will save lives.

Respiratory syncytial virus, or RSV, is common respiratory infection which mostly affects young children, including babies. The symptoms are usually mild and manageable at home; however, some children and adults can become extremely ill and require hospital treatment. There were more than 128,000 cases reported last year Australia-wide, causing symptoms that ranged from mild to life-threatening.

The Federal Department of Health and Aged Care’s disease surveillance tool shows cases in Victoria have increased from 3,400 cases in the first quarter of 2024 to 8,584 cases in the current, second quarter, surpassing Queensland in May.

More than half of all RSV cases are among infants and children under five. Research has found RSV is likely the most common reason for hospital presentation among infants aged 12 months or younger, and there has been a steady growth in global RSV hospitalisations since 2009.

Immunisation is available however, and clinical trials indicate an injectable antibody can reduce hospitalisations by 83%. Previously, the College welcomed action to tackle RSV through infant immunisation in Western Australia, New South Wales, and Queensland.

RACGP Victoria Chair Dr Anita Muñoz said immunisations for vulnerable infants will save lives. 

“This is an opportunity to prevent hospitalisation of babies and saves lives,” she said.

“Other states have taken action here, either making immunisations available to all new babies or through more targeted efforts.

“RSV is a serious disease that puts children in hospital every year. People may not realise the enormous health burden it places on children five and under in Australia. Not only is it likely the number one cause of hospitalisation among young children, up to a quarter of them need intensive care treatment. That’s an absolute nightmare for a young family to go through.

“With an immunisation program to match the one in Western Australia, we can keep children out of hospital beds, save families from a terrible experience, and be proactive about public health to relieve pressure on our health system, including our already under-pressure hospitals.”

~ENDS


About us:

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians.

Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here.


Contact details:

John Ronan
Media Adviser

Ally Francis
Media Adviser

Stuart Winthrope
Media Officer

Contact: 03 8699 0992media@racgp.org.au

Follow us on Twitter: @RACGP and Facebook.

Media

More from this category

  • Disability, Medical Health Aged Care
  • 20/12/2024
  • 17:36
Kuremara

Kuremara to Open a State-of-the-Art Activity Center in Milton, QLD, in January 2025

Kuremara, a trusted and leading NDIS-registered provider in Australia, is excited to announce the opening of its newest facility—a cutting-edge activity center in Milton,…

  • Contains:
  • Legal, Medical Health Aged Care
  • 20/12/2024
  • 17:29
JGA Saddler

BREAKING NEWS: Australian law firm takes on Johnson & Johnson for selling Australians ineffective medicine

Vision available: Lawyer and doctor VNR, editorial photos and radio grabs included can be found in this SharePoint File In-person lawyer interviews available by…

  • Contains:
  • Medical Health Aged Care
  • 20/12/2024
  • 12:01
NDARC/UNSW

ADHD drug shows promise for treating methamphetamine dependence, landmark Australian study shows

A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be repurposed as the first pharmacotherapy for people with methamphetamine dependence, according to a study published in Addiction. Results from the landmark ‘LiMA’ trial show that thepsychostimulant lisdexamfetamine can drastically reduce the need to use methamphetamine among those who are dependent on the illicit drug. Lead author and addiction medicine specialist Professor Nadine Ezard, who is Director of the National Centre for Clinical Research on Emerging Drugs (NCCRED), said the results were promising. "There is currently no pharmacotherapy approved for treating methamphetamine dependence," Professor Ezard said. “While further…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.